Safety of betaine as a novel food pursuant to Regulation (EC) No 258/97 by Turck, D et al.
SCIENTIFIC OPINION
ADOPTED: 25 October 2017
doi: 10.2903/j.efsa.2017.5057
Safety of betaine as a novel food pursuant to Regulation
(EC) No 258/97
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA),
Dominique Turck, Jean-Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait,
Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry J McArdle,
Androniki Naska, Monika Neuh€auser-Berthold, Gra_zyna Nowicka, Kristina Pentieva,
Yolanda Sanz, Alfonso Siani, Anders Sj€odin, Martin Stern, Daniel Tome, Marco Vinceti,
Peter Willatts, Karl-Heinz Engel, Rosangela Marchelli, Annette P€oting, Morten Poulsen,
Josef Rudolf Schlatter, Emanuela Turla and Henk van Loveren
Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver an opinion on betaine as a novel food (NF) pursuant to
Regulation (EC) No 258/97. The information provided on the composition, the specifications, the
batch-to-batch variability, stability and production process of the NF is sufficient and does not raise
concerns about the safety of the NF. The NF is proposed to be used in foods intended to meet
additional requirements for intense muscular effort with a maximum intake of 2.5 g/day of betaine for
sports people above 10 years of age. Based on the lowest BMDL05, which was derived from a chronic
toxicity study in rats in which a dose-related increase in platelet counts was observed, and the
anticipated daily intake of the NF in the target population, the Margins of Exposure are 3.6 and 5,
which are generally regarded as not sufficient. However, the total exposure to betaine from the diet
(about 830 mg/day) is not known to be associated with adverse effects. Moreover, no adverse effects
on platelet counts were noted in human intervention studies with exposure levels of 4 g/day of betaine
for up to 6 months. A significant increase in total and low-density lipoprotein (LDL)-cholesterol
concentrations was noted at intakes of 4 g/day of betaine in overweight subjects with metabolic
syndrome but not in healthy subjects, nor at intakes of 3 g/day. Thus, considering 4 g/day of betaine
as a reference point and applying an uncertainty factor of 10 to account for interindividual variability,
an amount of 400 mg/day of betaine (i.e. 6 mg/kg body weight (bw) per day for adults) in addition to
the background exposure is considered as safe. The Panel considers that the NF is safe to be used at
maximum intake of 6 mg/kg bw per day in the target population.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver an opinion on betaine as a novel food (NF) pursuant to
Regulation (EC) No 258/97. The assessment, which follows the methodology set in Commission
Recommendation 97/618/EC, is based on the data supplied in the original application, the initial
assessment by the competent authority of Finland, the concerns and objections of a scientific nature
raised by the other Member States and the responses of the applicant.
The NF is betaine, in anhydrous and monohydrate form, which is obtained from processing of sugar
beets (i.e. molasses, vinasses or betaine glycerol). The information provided on the composition, the
specifications, the batch-to-batch variability, stability and production process of the NF is sufficient and
does not raise concerns about the safety of the NF.
The NF is proposed to be used in foods intended to meet additional requirements for intense
muscular effort (i.e. carbohydrate-rich energy food products, carbohydrate-electrolyte solutions, and
protein/protein components) with a proposed intake of 2.5 g betaine per day. The target population
proposed by the applicant is sports people above 10 years of age (adolescents and adults). The 95th
percentile anticipated intake of the NF is 1.30 g/day (26.4 mg/kg body weight (bw) per day) for
adolescents and 2.93 g/day (35.7 mg/kg bw per day) for adults.
Betaine is naturally present in foods, such as beets, spinach and wheat flour. However, betaine
exposure from the diet does not only derive from the consumption of betaine-containing foods but
also from choline-containing foods as most choline is irreversibly oxidised to betaine in the body. The
total exposure to betaine resulting from dietary intake calculated from the sum of highest reported
mean intakes across studies can be estimated to be about 830 mg/day.
The available data indicate that, following oral ingestion, betaine is rapidly absorbed, released to
the portal circulation and transported to the liver where significant presystemic metabolism occurs.
Only a small amount of betaine and its metabolite dimethylglycine are excreted in the urine.
The Panel considers that there is no concern with respect to genotoxicity of the NF.
Several repeated-dose oral toxicity studies with the NF in rodents and piglets have been provided by
the applicant, some of which were assessed by the NDA Panel in 2005. At that time, the Panel could not
derive a no-observed-adverse effect level (NOAEL) for the NF from the 28-day and 90-day oral toxicity
studies.
The applicant has now provided a chronic oral toxicity and carcinogenicity study with the NF. Since
an increase in platelet counts in male rats was observed, which is regarded as a critical effect, already
occurred at the lowest dose level, the Panel considers that it is not possible to derive a NOAEL for this
combined chronic toxicity/carcinogenicity study. Therefore, the data on platelet counts in male rats
from the chronic oral toxicity study were subjected to benchmark dose (BMD) modelling. The lowest
BMDL05 of 131 mg/kg bw was considered by the Panel as the reference point (RP) for the risk
characterisation. The ratio between this RP and the anticipated daily intake of the NF in adults and
adolescents results in Margins of Exposure of 3.6 and 5, which are generally regarded as not sufficient.
However, the Panel notes that the total exposure to betaine resulting from dietary intake calculated
from the sum of highest reported mean intakes across studies (about 830 mg/day; i.e. 12 mg/kg bw
per day for adults and up to 19 mg/kg bw per day for adolescents) is not known to be associated with
adverse effects.
Moreover, the Panel notes that four human intervention studies are available with exposure levels
of 4 g/day of betaine supplementation (which corresponds to 57 mg/kg bw per day for adults) for up
to 6 months. In these studies, no adverse effects on platelet counts were noted. The Panel also notes
that a significant increase in total and low-density lipoprotein (LDL)-cholesterol concentrations have
been reported at intakes of 4 g/day of betaine in overweight subjects with metabolic syndrome but
not in healthy subjects, nor at intakes of 3 g/day. In this context, the Panel considers that 4 g/day of
betaine can be taken as a RP and that an uncertainty factor of 10 is sufficient to account for
interindividual variability. Therefore, an amount of 400 mg/day of betaine (i.e. 6 mg/kg bw per day by
using a mean bw of 70 kg for adults) in addition to the background exposure is considered as safe.
The Panel concludes that the safety of the NF, betaine, at the intended uses and use levels as
proposed by the applicant (2.5 g/day) has not been established.
The Panel considers that the NF is safe to be used at maximum intake of 6 mg/kg bw per day in
the target population (sports people above 10 years of age).
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 12 June 2015, the company DuPont Nutritional & Biosciences ApS submitted a request under Article
4 of the Novel Food Regulation (EC) No 258/971 to place on the market betaine as a novel food (NF).
On 21 October 2015, the competent authority of Finland forwarded to the Commission its initial
assessment report, which came to the conclusion that betaine meets the criteria for acceptance of a
NF defined in Article (3)1 of Regulation (EC) No 258/97.
On 23 October 2015, the Commission forwarded the initial assessment report to the other Member
States (MS). Several of the MS submitted comments or raised objections.
The concerns of a scientific nature raised by the MS can be summarised as follows:
• Information on whether the laboratories, which carried out the analyses on the NF, were
accredited in accordance with internationally recognised systems was missing.
• A MS questioned the no-observed-adverse effect level (NOAEL) proposed by the applicant (i.e.
5% betaine) for the chronic oral toxicity and carcinogenicity study owing to the observed
effects (e.g. decrease in mean corpuscular volume and mean corpuscular haemoglobin,
increase in number of platelet counts, decrease in total proteins and albumin concentrations,
decrease in albumin/globulin ratio and alkaline phosphatase; increase in liver and kidney
weights).
• A MS noted the small margin of exposure between the NF doses at which adverse effects were
observed in toxicological studies and the proposed daily intake of the NF.
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20022, the European Food Safety
Authority is asked to carry out the additional assessment for betaine as a NF in the context of
Regulation (EC) No 258/97.
EFSA is asked to carry out the additional assessment and to consider the elements of a scientific
nature in the comments raised by the other MS.
2. Data and methodologies
2.1. Data
The assessment of the safety of this NF is based on data supplied in the original application, the
initial assessment by the competent authority of Finland, the concerns and objections of a scientific
nature raised by the other MS and the responses of the applicant.
In accordance with Commission Recommendation 97/618/EC,3 betaine is allocated to Class 1.1, i.e.
‘pure chemicals or simple mixtures from non-GM sources; the source of the NF has a history of food
use in the Community’. The data are required to comply with the information required for novel foods
of Class 1.1, i.e. structured schemes I, II, III, IX, X, XI, XII and XIII of Commission Recommendation
97/618/EC. In the current opinion, these structured schemes are listed in Sections 3.1–3.9. The
intention is to add the NF to foods for intense muscular effort. This assessment concerns only risks
that might be associated with consumption of the NF at the proposed conditions of use, and is not an
assessment of the efficacy of betaine with regard to any claimed benefit.
2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of
29 July 1997 concerning the scientific aspects and the presentation of information necessary to
support applications for the placing on the market of novel foods and novel food ingredients and the
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
3 Commission Recommendation 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientific aspects and
the presentation of information necessary to support applications for the placing on the market of novel foods and novel food
ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and
of the Council.OJ L 253, 16.9.1997, p. 1–36.
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preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council.
3. Assessment
3.1. Specification of the Novel Food (NF)
The NF which is the subject of the application is betaine (N,N,N-trimethylglycine or carboxy-N,N,N-
trimethylmethanaminium), in anhydrous and monohydrate form. The NF is obtained from processing
of sugar beets (molasses, vinasses or betaine-glycerol).
The NF is intended to be placed on the market under different brand names (as anhydrous betaine:
BetafinTM BF20, Natural Extract BF, BetaPowerTM; as monohydrate betaine: BetafinTM AF20, Natural
Extract AF).
Betaine is naturally present in foods, such as beets, spinach and wheat flour (Patterson et al.,
2008).
The chemical formula of the anhydrous form of betaine is (CH3)3N
+CH2COO
– (CAS No: 107-43-7;
molecular mass 117.15 Da), whereas for the monohydrate form it is (CH3)3N
+CH2COO
–.H2O (CAS No:
590-47-6; molecular mass: 135.16 Da).
The specifications of the NF, which have been revised by the applicant upon EFSA’s request, are
presented in Table 1. The specifications include physical, chemical and microbiological parameters
together with their respective methods of analysis. Composition and purity of the anhydrous and
monohydrate forms of betaine are equivalent, with the exception of the water content, which is varied
by altering the conditions of the crystallisation phase of the manufacturing process. The specifications
of the NF are in line with the standards set by the Food Chemicals Codex (FCC, 2014).
In order to confirm that the manufacturing process is reproducible and adequate to produce a
product that is within the specifications as set in Table 1, the applicant provided batch-to-batch
analyses of three batches of the NF in its anhydrous and monohydrate form (Table 2).
The NF complies with the current legislation in terms of mycotoxins, dioxins and dioxin-like-PCB
(polychlorinated biphenyls), and polycyclic aromatic hydrocarbons. Analyses for pesticides on two
batches of betaine (anhydrous form) did not report residues of pesticides, except for Glyfos® which
was reported at levels below 0.01 mg/kg.
Safety of betaine
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Table 1: Specifications of the NF (anhydrous and monohydrate form)
Parameter Specifications Method of analysis
Physical appearance Free-flowing white crystals Visual inspection
Colour Max. 20 International Commission for Uniform Methods of Sugar
Analysis (ICUMSA GS2/3-10)
Betaine Min. 99% on dry basis HPLC(a)
Moisture Max. 2% anhydrous
Max. 15% monohydrate
Halogen drying (thermogravimetric method) Internal
Analytical Method 2.10.3.3.-59.3
Ash Max. 0.1% Conductometric
Chloride Max. 50 mg/kg Dionex Ion chromatography(b)
Sulfate Max. 100 mg/kg Dionex Ion chromatography(b)
pH (5% solution) 5–7 pH meter
Ethanol < 10 mg/kg HS-GC/MS (in house method accredited by EuroFins)(c)
Residual proteins Max. 1,000 lg/g Roti-Nanoquant K880 (Carl Roth GmbH) protein
quantification assay (Modified Bradford protein assay)(d)
Heavy metals
Arsenic < 0.1 mg/kg EN 15763:2009, ICP-MS
Lead < 0.05 mg/kg EN 15763:2009, ICP-MS
Iron < 0.1 mg/kg EN 15763:2009, ICP-MS
Cadmium < 0.01 mg/kg EN 15763:2009, ICP-MS
Selenium < 0.2 mg/kg EN ISO 17294-2-E29, ICP-MS
Mercury < 0.005 mg/kg EN 15763:2009, ICP-MS
Microbiological count
Total viable count Max 100 cfu/g ISO 4833
Yeast Max 10 cfu/g NMKL 98
Mould Max 10 cfu/g NMKL 98
Coliforms Absent in 10 g ISO2152-8
Salmonella Absent in 25 g ISO 2152-8
cfu: colony forming units; HPLC: high-performance liquid chromatography; ICP-MS: inductively coupled plasma mass
spectrometry; HS-GC/MS: headspace gas chromatography/mass spectrometry; ICUMSA: International Commission for Uniform
Methods of Sugar Analysis.
Limits of detection: (a) 5 mg/kg; (b) < 5 mg/kg; (c) < 10 mg/kg; (d) 25 lg/g.
Safety of betaine
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Table 2: Batch-to-batch analyses of the NF (anhydrous and monohydrate forms)
Parameter Specifications
Analytical data for anhydrous betaine Analytical data for monohydrate betaine
Batch
4311946923
Batch
4311782722
Batch
43123053786
Batch
4311788559
Batch
4312102070
Batch
4312255008
Physical appearance Free-flowing
white crystals
Conforms to
specification
Conforms to
specification
Conforms to
specification
Conforms to
specification
Conforms to
specification
Conforms to
specification
Colour Max. 20 2 0 0 0 4 1
Betaine Min. 99% (w/w on
dry weight basis)
99.6 99.2 100.0 99.1 99.3 99.8
Moisture Max. 2% w/w
anhydrous
Max. 15% w/w
monohydrate
0.8 0.8 0.7 13 13.2 13.4
Ash Max. 0.1% w/w 0.0027 0.0032 0.0017 0.0025 0.0056 0.0032
Chloride Max. 50 mg/kg 4 7 3 5 5 9
Sulfate Max. 100 mg/kg 10 2 3 5 4 10
pH (5% solution) 5–7 6.7 6.5 6.6 6.5 6.6 6.6
Ethanol < 10 mg/kg < 10 (Batch
4311989522)
< 10 (Batch
4311991121)
< 10 (Batch
4312437848)
– – –
Residual proteins < 1,000 lg/g 220 (Batch
4312920393)
240 (Batch
4312878054)
220 (Batch
4312614128)
Arsenic < 0.1 mg/kg < 0.1* < 0.1* < 0.1* < 0.1* < 0.1* < 0.1*
Lead < 0.05 mg/kg < 0.05* < 0.05* < 0.05* < 0.05* < 0.05* < 0.05*
Iron < 0.1 mg/kg < 0.1* < 0.1* < 0.1* < 0.1* < 0.1* < 0.1*
Cadmium < 0.01 mg/kg < 0.01* (Batch
4312158590)
< 0.01* (Batch
4312346281)
< 0.01* (Batch
4311527904)
– – –
Selenium < 0.2 mg/kg < 0.2*(Batch
4312158590)
< 0.2* (Batch
4312346281)
< 0.2* (Batch
4311527904)
– – –
Mercury < 0.005 mg/kg < 0.005* (Batch
4312158590)
< 0.005* (Batch
4312346281)
< 0.005* (Batch
4311527904)
– – –
Total viable count Max 100 cfu/g < 100 < 100 < 100 < 100 < 100 < 100
Yeast Max 10 cfu/g < 10 < 10 < 10 < 10 < 10 < 10
Mould Max 10 cfu/g < 10 < 10 < 10 < 10 < 10 < 10
Coliforms Absent in 10 g Absent Absent Absent Absent < 10 < 10
Salmonella Absent in 25 g Absent Absent Absent Absent < 10 < 10
*: Below limits of detection; –: data not available; cfu: colony forming units.
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One of the two test facilities, in which the analyses were carried out, was accredited in accordance
to ISO 17025 standard, whereas the other one was certified in accordance to ISO 9001:2008 and ISO
14001:2004.
The Panel considers that the information provided on the composition, the specifications and the
batch-to-batch variability of the NF is sufficient and does not raise safety concerns.
3.1.1. Stability of the NF
The applicant provided the results from stability tests performed with three batches of the NF
(anhydrous and monohydrate form) in the original packaging (carton with a polyethylene inner bag)
and stored at 15–25°C over a period of 40 months. These data show that the NF remains within the
specifications, with the exception of the moisture content for one batch of anhydrous betaine which
slightly exceeded the specified limit after 40 months (2.1% vs 2%). Based on these data, the applicant
proposed a shelf-life of 36 months for the NF (anhydrous and monohydrate form) when stored in the
unopened original packaging (cartons with a polyethylene inner bag) and protected from humidity.
The Panel considers that the data provided sufficient information with respect to the stability of the
NF.
3.1.2. Stability under the intended conditions of use
The stability of the NF, when used as an ingredient in isotonic ready-to-drink beverages (non-
carbonated), has been investigated in two formulations at different pH (pH 3 and pH 4, respectively).
The two formulations were stored at 20°C or 35°C, in light or dark conditions, for up to 12 months,
and tested for betaine content (by liquid chromatography/electrospray ionisation-isotope dilution mass
spectrometry (LC/ESI-IDMS)) at different time points (3, 6, 9 and 12 months).
This study reported a maximum loss of betaine of 10% after 12 months. Based on these results
and the stability of the NF over 40 months, the applicant does not expect to see a significant loss of
betaine content in beverages.
The Panel considers that the data provided sufficient information with respect to the stability of the
NF under the intended conditions of use.
3.2. Effect of the production process applied to the NF
Betaine is extracted with hot water from either: (i) non-genetically modified (GM) sugar beet
molasses (the syrupy by-product obtained from sugar refining of sugar beets), (ii) non-GM sugar beet
vinasses (the by-product obtained from fermentation where molasses are used as a carbon source)
using Saccharomyces cerevisiae (baker’s yeast) or (iii) betaine-glycerol (the product obtained by
further separation/purification of non-GM sugar beet vinasses). After several chromatographic
purification steps, betaine can be crystallised either as the anhydrous or monohydrate form by
adjusting the conditions of the crystallisation.
Upon EFSA’s request, the applicant provided a detailed description of the steps applied to produce
vinasses and betaine-glycerol from beet molasses.
Upon EFSA’s request, the applicant indicated the control steps (e.g. microfiltration) which are in
place to ensure that S. cerevisiae is removed from the final product.
The NF (anhydrous and monohydrate form) is produced in accordance with Good Manufacturing
Practices and Hazard Analysis and Critical Control Points principles. The quality controls in place at the
manufacturing site are certified by Lloyd’s Register Quality Assurance, Evira as well as by the Local
Health Authority periodically conducting a review.
The Panel considers that the production process is sufficiently described and does not raise safety
concerns.
3.3. History of the organism used as a source of the NF
Betaine is produced from sugar beet (Beta vulgaris L.), which belongs to the Amaranthaceae family.
Sugar beet originates from Asia and grows in temperate regions in Europe and North America.
Sugar beet is mainly used for sugar production. Sugar beet are planted in spring and harvested in
autumn. In the initial growing period, sugar is accumulated in the leaves for the plant growth
processes, whereas in the late growing period sugar is accumulated in the roots. Typically, sugar beet
roots consist of 75.9% water, 18% sugars, 2.6% non-sugar components and 5.5% pulp (FAO, 1994,
2013; CFIA, 2012).
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Sugar beet has a long history of use as a food ingredient, in particular as a source of sweets
among the Egyptians, Indians, Chinese, Greeks and Romans (Deerr, 1950).
Products derived from sugar beets (e.g. sugar, fibre, syrups) are currently used as foods or food
ingredients or ingredients in animal feeding in Europe and in the USA.
The applicant indicated that sugar beet syrups, which contain up to 3% of betaine, have been sold
in Europe prior to 1997.
3.4. Anticipated intake/extent of use of the NF
The NF is proposed to be used in foods intended to meet additional requirements for intense
muscular effort: carbohydrate-rich energy food products, carbohydrate-electrolyte solutions, and
protein/protein components. The composition of these foods is described in the report on ‘foods
intended to meet the expenditure of intense muscular effort’ by the Scientific Committee on Food (SCF,
2001).
The proposed intake of betaine is 2.5 g/day. Proposed food uses and maximum use levels of the
NF are presented in Table 3.
The applicant indicated that foods added with the NF will be packaged in single portion sizes with
labelling indications on the amount of betaine per serving (1.25 g) and the recommended daily intake
(2.5 g betaine per day).
The target population proposed by the applicant is sports people above 10 years of age
(adolescents and adults).
The applicant indicated that betaine fortified foods may replace betaine food supplements in sports
people.
3.4.1. Intake of the NF from fortified foods
In a tiered approach, the applicant provided estimates of the anticipated intake of the NF based on
the summary statistics from the EFSA Comprehensive European Food Consumption Database which
generally leads to an overestimation of anticipated daily intakes.
For a refined intake estimate of the NF, the applicant used individual data from the UK National Diet
and Nutrition Survey (NDNS) Rolling Survey Programme covering the period 2008–2011 for teenagers
and adults (NDNS, 2012).
In the absence of specific foods for sports people within the UK food categorisation system, specific
food categories were selected to represent the foods to which the NF is intended to be added. The
‘representative’ food categories and use levels which were used to estimate the anticipated daily intake
of the NF are presented in Table 4.
Table 3: Proposed uses and maximum use levels of the NF
EFSA Food
classification system
Proposed uses
NF per
serving (g)
Typical serving
size (g)(a)
Maximum use level of the
NF (g per 100 g of food)
Carbohydrate-rich
energy food products
Cereal bars 1.25 60 2.1
Carbohydrate-rich
drink powders
1.25 15–20 g (powder);
250–500 (RTD)
6.3–8.3 (powder);
0.25–0.5 (RTD)
Carbohydrate-
electrolyte solutions
Isotonic ready-to-
drink beverages
(non-carbonated)
1.25 500 0.25
Protein and protein
components
Protein bars 1.25 60 2.1
Protein-rich drink 1.25 15–20 g (powder);
250–500 (RTD)
6.3–8.3 (powder);
0.25–0.5 (RTD)
NF: novel food; RTD: ready-to-drink.
(a): Serving size and proposed use per made-up (RTD) beverage and based on manufacturers information on typical UK
products.
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Based on the UK food categories indicated in Table 4 and the food consumption data from the UK
NDNS Rolling Survey Programme (2008–2011), the mean and 95th percentile anticipated daily intake
of the NF for teenagers and adults have been calculated (Tables 5 and 6, on a g and on a mg/kg body
weight (bw) basis, respectively).
The 95th percentile anticipated daily intake of the NF is 1.30 g (26.4 mg/kg bw) for teenagers and
2.93 g (35.7 mg/kg bw) for adults.
Information on the contribution of each food category selected from the UK NDNS Survey (Table 4)
to the total anticipated daily intake of the NF was provided by the applicant: in adolescents, isotonic
drinks would contribute to 70–81%, meal replacement beverages to 12–31% and drink powders to
7%; in adults, drink powders would contribute to 48–51%, isotonic drinks to 7–46%, meal
replacement to 1–33% and protein/cereal bars to 6–9%.
The applicant also provided two reports on the market and consumer’s attitude towards sports
nutrition products in Norway, Sweden and Denmark (Anestad et al., 2009; Schjøll et al., 2009). The
Panel considers that these reports do not provide information on the estimated intake of the NF from
fortified foods.
3.4.2. Intake of betaine from the background diet
In the previous opinion on the safety of betaine as a NF (EFSA, 2005), the intake of betaine from
the background diet was reported to range from about 500 mg/day (average) to 2.5 g/day for a high
seafood diet. The high intake of 2.5 g/day was reported in a review article on ‘betaine in human
nutrition’ by Craig (2004). This estimate was based on the betaine content in foods reported by Zeisel
et al. (2003) and an unpublished exposure assessment referred to by Craig (2004). A similar range
(i.e. 0.5–2.0 g/day) was also indicated in the EFSA health claim opinion on betaine in 2011 (EFSA NDA
Panel, 2011).
Table 6: Estimate of the anticipated daily intake of the NF (mg/kg bw per day) from the UK NDNS
Data (population of consumers only)
Population group
% of
consumers
N of
consumers
Mean (mg/kg bw
per day)
95th Percentile
(mg/kg bw per day)
All teenagers (11–18 years old) 8.5 56 9.6 26.4
All adults (19–64 years old) 3.8 43 10.6 35.7
Table 4: UK food categories and NF use levels which were used to estimate the intake of the NF
from the UK NDNS Survey Data
UK food categories
NF per
serving (g)
Serving
size (g)
NF use level (g of
NF per 100 g)
Flavoured beverages Drink powders(a) 1.25 500 0.25
Isotonic ready-to-drink
beverages
1.25 500 0.25
Foods intended for particular
nutritional uses
Protein or cereal bars 1.25 60 2.1
Meal replacement
beverages
1.25 250 0.5
NF: novel food.
(a): Serving size and proposed use levels is per made up beverage; serving sizes are based on typical servings of beverages or
meal replacement bars in the UK based on manufacturers’ information.
Table 5: Estimate of the anticipated daily intake of the NF (g/day) from the UK NDNS Data
(population of consumers only)
Population group
% of
consumers
N of
consumers
Mean
(g/day)
95th
Percentile (g/day)
All teenagers (11–18 years old) 8.5 56 0.59 1.30
All adults (19–64 years old) 3.8 43 0.89 2.93
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The present application provides a revised intake estimate of betaine from the background diet on
the basis of more recent data from the United States Department of Agriculture (USDA) database
(Patterson et al., 2008). In the report by Patterson et al. (2008), the betaine content in some foods
(e.g. seafood and spinach) was reduced as compared to the previous version of the USDA database
(Howe et al., 2004) and the levels previously reported by Zeisel et al. (2003) owing to a technical
problem in the analysis which led to an overestimation of the betaine content in some foods.
According to Patterson et al. (2008), betaine content is highest in quinoa (630 mg/100 g), followed
by ready-to-eat breakfast-cereals (up to 360 mg/100 g), beets and spinach (120 mg/100 g), wheat
bread (85 mg/100 g), spaghetti (68 mg/100 g), snacks (50 mg/100 g), white bread and chicken
(30 mg/100 g).
The applicant has also provided several studies on the dietary intake of betaine in adults, the
majority of which was conducted outside Europe, except for the studies by Detopoulou et al. (2008),
Dalmeijer et al. (2008) and Price et al. (2010).
In Greek adults, Detopoulou et al. (2008) reported mean betaine intakes of 306 mg/day in men
(n = 1,514) and 314 mg/day in women (n = 1,528) who participated in the ATTICA survey. Dietary
intake was assessed through a validated semi-quantitative food-frequency questionnaire. Dalmeijer
et al. (2008) reported mean betaine intakes of 241 mg/day in 16,165 Dutch women who participated
in the European Prospective Investigation into Cancer and Nutrition cohort study. Dietary intake was
assessed with a food-frequency questionnaire. In these studies, the betaine content in foods was
based on the 2004 USDA database (Howe et al., 2004).
In the intervention study by Price et al. (2010) in Northern Ireland in 79 adults, a mean betaine
intake of 127 mg/day was reported through 4-day food diaries. The betaine content in foods was
based on the USDA database by Patterson et al. (2008).
Among the remaining studies provided, which were conducted outside Europe, Ross et al. (2014)
presented the results on betaine intakes from 17 studies in which the data on betaine content in foods
were adjusted when the 2004 USDA database was used. Among these studies the mean intake of
betaine ranged from 70 to 154 mg/day, with median betaine intakes ranging from 40 to 298 mg/day.
Mygind et al. (2013) reported a mean betaine intake of 178 mg/day and a 95th percentile of
300 mg/day in 125 New Zealander women. Dietary intake was assessed through a 3-day weighed food
record and the betaine content in foods was based on the USDA database by Patterson et al. (2008).
Studies in USA and China reported mean betaine intakes up to around 220 mg/day (Shaw et al.,
2004; Fischer et al., 2005) and 310 mg/day (Zeng et al., 2014; Zhang et al., 2013). Dietary intakes
were assessed through a 3-day food record, or food-frequency questionnaires, and the betaine
content in foods was based on the database by Zeisel et al. (2003).
Overall, the mean betaine intake estimate from the background diet ranges approximately between
70 and 300 mg/day across the studies. On this basis, the Panel notes that the mean betaine daily
intake estimate from the background diet is at least eight times lower than the maximum intended
daily intake of the NF from fortified foods (2.5 g/day).
However, betaine exposure from the diet does not only derive from the consumption of betaine-
containing foods but also from choline-containing foods as most choline is irreversibly oxidised to
betaine in the body.
As reported in the EFSA opinion on Dietary Reference Value on choline (EFSA NDA Panel, 2016),
the mean choline intake estimates in adults ranged from 269 to 468 mg/day from national surveys in
seven EU countries (Vennemann et al., 2015), and were between 265 and 415 mg/day in three studies
conducted in non-EU countries (Chu et al., 2012; USDA, 2012; Mygind et al., 2013). That opinion also
reported that in children aged 10–17 years, the choline intake estimate ranged between 244 and
373 mg/day based on seven surveys in EU countries.
Publications on choline intake estimates were provided by the applicant (FASEB, 1981; Zeisel, 1981;
USDA, 2010; Mygind et al., 2013).
Based on the data above, the mean choline intake estimate from the background diet ranges
between 269 and 468 mg/day. Assuming that all dietary choline is ultimately oxidised to betaine, the
mean exposure to betaine would range between 302 and 526 mg/day by considering the molecular
weight of betaine and choline.
The total exposure to betaine resulting from dietary intake calculated from the sum of highest
reported mean intakes across the studies (i.e. 300 mg/day from betaine-containing foods and
526 mg/day from choline-containing foods) can be estimated to be about 830 mg/day. The
Panel notes that the background exposure to betaine from the diet is at least 3 times lower than the
maximum intended daily intake of the NF from fortified foods (2.5 g/day).
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3.4.3. Intake of betaine from other sources
The applicant indicated that betaine-containing food supplements (serving size about 1.2–1.5 g
betaine) are currently available in the EU market and are used by sports people. The applicant
indicated that the proposed uses of the NF (i.e. foods intended to meet additional requirements for
intense muscular effort) will partially or wholly replace betaine-containing food supplements.
Anhydrous betaine is used as a medicine for the treatment of a rare disease, homocystinuria, at
daily doses of 100 mg/kg bw (EMA, 2007).
3.5. Information from previous exposure to the NF or its source
Information from previous exposure to the NF or its source is provided in Sections 3.3 and 3.4.
3.6. Nutritional information on the NF
Betaine is a natural component in a variety of foods (see Section 3.4.2). Betaine is also produced in
the human body through the irreversible oxidation of free choline in the liver and kidneys, and it acts
as a methyl donor in the methionine cycle (see Section 3.8.1).
Serum vitamin B12, folate and plasma vitamin B6 concentrations were assessed in healthy
individuals in studies on the effect of betaine supplementation on plasma homocysteine concentrations
(Schwab et al., 2002, 2011; Steenge et al., 2003; Olthof et al., 2006). Steenge et al. (2003) reported a
statistically significant increase in serum vitamin B12 concentrations following intake of 6 g/day of
betaine for 6 weeks. However, the authors attributed this effect to a reduction in serum vitamin B12
concentrations in the placebo group which was mainly due to a substantial drop in one subject. Apart
from this effect reported by Steenge et al. (2003), no significant differences in these vitamin
concentrations were observed at betaine intakes of 6 g/day for 6 weeks up to 4 g/day for 6 months as
compared to the placebo group (Schwab et al., 2002, 2011; Steenge et al., 2003; Olthof et al., 2006).
In a kinetic study on L-[2H3-methyl-1-
13C]methionine metabolism in healthy young adult men,
betaine supplementation of 3 g/day for 4 days significantly increased not only plasma methionine
concentrations, but also the rate of methionine utilisation via transmethylation as well as the rate of
methionine oxidation (Storch et al., 1991). The increased rate of methionine oxidation measured in this
study was equivalent to 30% of the dietary methionine intake and the total rate of methionine
oxidation was essentially equivalent to the total intake of methionine during the intervention period.
Based on these results, Storch et al. (1991) hypothesised that excess intake of betaine may increase
the dietary requirement for methionine, but simultaneously pointed out that subjects were not studied
during the fasting or post-absorptive phase of amino acid metabolism, and therefore, an effect prior to
betaine supplementation at an early post-absorptive period or at a total over a 24-h period could not
be ruled out. In another study in healthy men and women ingesting 6 g/day of betaine for 6 weeks,
methionine concentrations were higher compared to the placebo group both in fasting plasma and
after methionine loading (Olthof et al., 2003) which supports the hypothesis that betaine is available
as methyl donor (Schwahn et al., 2003) for the remethylation of homocysteine to methionine. Based
on available studies, the Panel notes that the overall impact of betaine on methionine requirement has
not been demonstrated.
The Panel considers that consumption of the NF is not nutritionally disadvantageous.
3.7. Microbiological information on the NF
To ensure the absence of microorganisms, the NF is tested for yeasts, moulds, coliforms and
Salmonella spp. as described in the specifications (Table 1). The results of analyses for microorganisms
in three batches of the NF are presented in Table 2.
The Panel considers that the microbiological information provided does not raise safety concerns.
3.8. Toxicological information on the NF
The safety of betaine as a NF was evaluated by the NDA Panel in 2005 (EFSA, 2005). Since the
finalisation of that evaluation, new data on the safety of the NF have become available and have been
provided by the applicant in the context of the current NF application.
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3.8.1. Absorption, distribution, metabolism and excretion
Information on kinetics and metabolism of betaine has been previously assessed by the
Panel (EFSA, 2005).
In the context of the current application, the applicant provided a new study on the kinetics and
metabolism of betaine (Schwab et al., 2006). Using a randomised, double-blind, cross-over design,
healthy volunteers (three men and seven women) were administered single doses of 1, 3 and 6 g
betaine in orange juice. Blood samples were taken up to 24 h after administration, and the 24-h urine
was collected. The levels of betaine and its metabolite dimethylglycine (DMG) were determined in
plasma and urine. Orally administered betaine had an immediate and dose-dependent effect on serum
betaine concentration. Maximum concentrations (Cmax) were reached 40, 60 and 80 min (Tmax) after
administration of 1, 3 and 6 g, respectively. Betaine was rapidly absorbed with T1/2abs between 11 and
23 min and T1/2dist between 28 and 49 min, and elimination occurred with T1/2elim between 7.5 and
8.8 h. A small proportion of ingested betaine was excreted via urine during 24 h; the calculated sum
of betaine and its first metabolite DMG in urine was 3.2%, 4.3% and 7.4% of the ingested amount of
1, 3 and 6 g betaine, respectively. The kinetic parameters reported by Schwab et al. (2006) are largely
consistent with those observed in the study by Schwahn et al. (2003), which was assessed by the
Panel in 2005 (EFSA, 2005), with the exception of the elimination half-life (T1/2elim) of betaine which
is shorter in the study by Schwab et al. (2006) as compared to the study by Schwahn et al. (2003)
(7.5–8.8 h vs 14.4 h, respectively).
Four randomised, placebo-controlled, double-blind human intervention studies reported plasma
and/or urine levels of betaine and/or its metabolite DMG following supplementation of betaine at doses
up to 6 g over periods up to 6 months (Schwab et al., 2002, 2011; unpublished study report, undated;
Tiihonen et al., 2016). The description of these human intervention studies is provided in
Section 3.8.7.
Schwab et al. (2002) reported that betaine supplementation of 6 g/day for 12 weeks induced a
> 10-fold increase in plasma betaine concentrations from the normal range of about 20 lmol/L.
Schwab et al. (2011) reported that 6 months of 4 g/day of betaine supplementation leads to an
increase in plasma betaine (from 25.6  9.6 at day 0 to 187.3  107.8 at 6 months), plasma DMG
(from 15.8  3.3 at day 0 to 51.8  55.6 at 6 months) and urine betaine (from 82  52.6 day 0 to
954.1  1,186.8 at 6 months) concentrations (lmol/L) as compared to the placebo group (betaine
and DMG plasma concentrations were statistically significantly different between groups; p < 0.001).
Another study (unpublished study report, undated) reported an increase in plasma and urine
betaine concentrations (plasma betaine: from 31.4  9.5 at day 0 to 168.8  100.2 at week 12; urine
betaine: from 145.8  82.0 at week 0 to 993.0  1,083.0 at week 12) and plasma DMG (from
5.1  0.9 at week 0 to 28.8  30.7 at week 12) concentrations (lmol/L) in subjects who received
4 g/day of betaine for 12 weeks as compared to the placebo group (plasma betaine and DMG
concentrations were statistically significantly different between groups; p < 0.001).
After 12 weeks of betaine supplementation (3 g/day), Tiihonen et al. (2016) reported that betaine
plasma concentrations were higher in the betaine group as compared to the placebo group
(132.7  52.7 vs 47.7  9.8 lmol/L, respectively; p < 0.005).
The available data indicate that, following oral ingestion, betaine is rapidly absorbed, released to
the portal circulation and transported to the liver where significant presystemic metabolism occurs.
Only a small amount of betaine and its metabolite DMG are excreted in the urine.
3.8.2. Genotoxicity
The applicant provided a series of genotoxicity studies on the NF (betaine monohydrate; > 99%
purity), which were assessed by the Panel in 2005 (EFSA, 2005): a bacterial reverse mutation test
using Salmonella Typhimurium, an in vitro mammalian chromosome aberration test using human
lymphocytes and an in vivo bone marrow micronucleus test using mice (Unpublished study reports,
1989a,b,c). These studies were conducted in compliance with the Organisation for Economic
Co-operation and Development (OECD) principles of Good Laboratory Practice (GLP) (OECD, 1982).
No genotoxicity was observed in these studies.
Even though the genotoxicity testing strategy is not fully in line with current EFSA
recommendations (EFSA Scientific Committee, 2011) as regards the in vitro mammalian micronucleus
test, the Panel considers that there are no concerns with respect to genotoxicity of the NF.
Safety of betaine
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2017;15(11):5057
3.8.3. Acute toxicity studies
The acute oral toxicity study in rats (unpublished study report, 1990), which was conducted in
compliance with the principles of GLP and in accordance with OECD Test Guideline No. 401 (OECD,
1987), has been previously assessed by the Panel (EFSA, 2005). The LD50 was determined to be
approximately 11 g/kg bw.
3.8.4. Repeated-dose toxicity studies
Subacute and subchronic toxicity studies
The applicant referred to the 28-day and 90-day oral toxicity studies in Sprague–Dawley rats by TNO
BIBRA (Unpublished study reports, 2001a,b) and by Hayes et al. (2003), which have been previously
assessed by the Panel (EFSA, 2005). The studies by TNO BIBRA (Unpublished study report, 2001a,b)
were conducted in compliance with the principles of GLP. Notwithstanding EFSA’s request, no information
was provided whether the study by Hayes et al. (2003) was conducted in compliance with GLP.
Upon EFSA’s request for information on the test material used in these studies, the applicant
provided the certificate of analysis, which indicates a purity of at least 99% (by high-performance
liquid chromatography (HPLC)) of the test material (anhydrous betaine) and compliance with the
specifications for the NF.
In 2005, the Panel concluded that results of animal studies do not prove satisfactorily that betaine
is safe. Subacute and subchronic toxicity studies in Sprague–Dawley rats (i.e. Unpublished study
reports, 2001a,b) have clearly shown that the liver is the main target organ in rats. The dose-related
effects, more pronounced in females, included increased liver weight, hepatocellular vacuolisation and
increased serum concentrations of liver enzymes. The changes were largely reversible. They were
observed, however, at all tested dose levels, even after a short treatment period of 14 days.
Therefore, a NOAEL could not be established. Another study (i.e. Hayes et al., 2003), in which betaine
was given to female Sprague–Dawley rats and in which ‘no apparent abnormalities of clinical
importance’ were reported, did not comply with OECD and GLP requirements for studies. As the
available studies did not allow the derivation of a NOAEL for betaine and data on reproduction and
developmental toxicity were lacking, an acceptable daily intake could not be established from the
animal data (EFSA, 2005).
The applicant has now provided a tolerance study in piglets (unpublished study report, 2012),
which has been previously evaluated by the EFSA FEEDAP Panel in the context of an application for
authorisation of betaine (anhydrous) as a nutritional additive to be used in feed and water for drinking
for all animal species (EFSA FEEDAP Panel, 2013).
In this study, betaine was administered to piglets at dose levels up to 20,000 mg/kg feed (which
corresponds to 2% of betaine in the diet) for 6 weeks. Upon an EFSA request for information on the
test material (anhydrous betaine), the applicant provided the certificate of analysis, which indicates a
purity of 99% (by HPLC) and compliance with the specifications of the NF.
The FEEDAP Panel indicated that the only biologically relevant effects observed in this study were a
dose-dependent decrease in serum phosphorus and increased hepatocellular vacuolisation in the
highest betaine dose group (2% of betaine in the diet) as compared to the control group. The latter
finding appears to be in agreement with the observation of the NDA Panel (EFSA, 2005) that subacute
and subchronic toxicity studies have clearly shown that the liver is the main target organ in rats.
However, the FEEDAP Panel noted that in the study in piglets, increased liver weight and increased
liver enzymes were not observed.
The applicant has also referred to a 4-week study in rats, which was mentioned in a Scientific
Discussion published by the European Medicines Agency (EMA) in the context of the evaluation of
anhydrous betaine for use as a therapeutic agent in patients with homocystinuria (EMA, 2007). In this
study, groups of 10 male and 10 female rats (strain not specified) were administered the test material
in the diet at dose levels of 0 (control), 1.3 or 2.6 g/kg bw per day for 29 days. According to EMA, the
no-observed-effect level (NOEL)/NOAEL was 2.6 g/kg bw per day, the highest dose tested.
In addition, the applicant has referred to several repeated-dose studies in mice and rats, which
have not been included in the previous application of betaine (Barak et al., 1993, 1994; Kim and Kim,
2002, 2005; Balkan et al., 2005; Schwahn et al., 2007; Wang et al., 2010; Okada et al., 2011). In
these studies, betaine was administered at doses between 300 and 3,770 mg/kg bw per day to
different strains of mice or rats, for periods between 2 weeks and 1 year. The studies were designed
to assess the effects of betaine in ameliorating certain disease states, particularly of the liver.
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Compared with the relevant toxicological studies described in previous paragraphs, group sizes were
smaller and a limited number of endpoints were examined. The Panel thus concludes that these
additional studies do not add relevant information to the risk assessment of the NF.
Chronic toxicity and carcinogenicity studies
When betaine was first evaluated by the NDA Panel in 2005 (EFSA, 2005), long-term toxicity
studies were not available. The applicant has now provided a chronic oral toxicity and carcinogenicity
study in F344/DuCrj rats (unpublished study report, 2002). No GLP certificate was provided and no
reference was made to any national or international guidelines followed. The Panel notes, however,
that the design of the study was similar to that recommended in OECD TG 453 for combined chronic
toxicity/carcinogenicity studies (OECD, 2009). In the chronic part of the study, groups of 10 males and
10 females (individually housed) were provided a standard rodent diet containing 0.0% (control),
1.0% (low dose), 2.3% (mid dose) or 5.0% (high dose) of the NF (purity 99.9%) for 52 weeks. The
average betaine intake was determined to be 426, 975 and 2,104 mg/kg bw per day in males of the
low-, mid- and high-dose groups, respectively, and 515, 1,142, and 2,442 mg/kg bw per day in
females of the low-, mid- and high-dose groups, respectively. In the carcinogenicity part, groups of 50
male and 50 female rats (individually housed) were administered diets containing 0% (control), 1%
(low dose) or 5% (high dose) betaine for 104 weeks. In this study the average betaine intake was
determined to be 378 and 1,802 mg/kg bw per day in males of the low- and high-dose groups,
respectively, and 458 and 2,141 mg/kg bw per day in females of the low- and high-dose groups,
respectively. Test and control diets, as well as water were provided throughout the study to ensure
ad libitum feeding. Upon EFSA’s request for information on the test material used in these studies, the
applicant indicated that the test material (betaine, with 99.9% purity) was not produced by the
applicant but by another Japanese company which followed the applicant’s patented method.
In the chronic part of the study, all animals survived the treatment period and no treatment-related
changes in animal performance were identified. Body weights of female rats of the high-dose group were
statistically significantly lower compared with the control group at weeks 4, 5 and 10, but final body
weights did not differ. Feed intake of males and females in all groups was significantly lower than in the
control group during different time periods; in females, there was a weak correlation to dose and body
weight. Haematology and clinical chemistry analyses were conducted only at the end of the treatment
period. Mean corpuscular volume (MCV) was lower (dose-related) in males (mid- and high-dose group)
and females (all three test groups) as compared with the control group. In males and females of the
high-dose group, mean corpuscular haemoglobin (MCH) was significantly lower. Males of all test groups
showed a significantly higher platelet count (dose-related), and a trend is also noted in females. Total
protein plasma concentrations were significantly reduced in the high-dose group (both sexes), albumin
plasma concentrations were lower in the high-dose group (both sexes) and females of the mid-dose
group, and the albumin/globulin ratio was lower in males (all three test groups) and females (mid- and
high-dose group). Males showed significant and dose-related reductions in the activities of alkaline
phosphatase (ALP) (mid- and high-dose group), alanine transaminase (ALT) and aspartate transaminase
(AST) (all test groups). In females, only AST was significantly reduced in the high-dose group, but ALP
and ALT activities showed a trend in this direction. As compared to control groups, the activity of
c-glutamyltransferase was significantly lower in males but higher in females (both in the mid- and high-
dose groups). Females also showed lower concentrations of bilirubin (mid- and high-dose group) and
calcium (high-dose group). Urinalysis was not conducted. Organ weight determinations at necropsy
showed a significantly higher kidney weight in high-dose males (relative weight) and females (absolute
and relative weight) and a higher liver weight in high-dose females (absolute and relative weight). Males
of the low- and mid-dose groups showed a significantly lower relative heart weight. Females of the low-
dose group showed a significantly lower absolute heart weight, whereas females of the mid-dose group
showed a significantly lower relative heart weight. Macroscopic examinations revealed no treatment-
related effects, and in the microscopic examinations of tissues the incidence and severity of
histopathological changes was comparable in all groups.
In the carcinogenicity part of the study, there was no significant difference in the overall survival
rate between betaine groups and the control group. The number of rats, which died or were killed in a
moribund state, was 8 (control), 7 (1% betaine) and 4 (5% betaine) in males, and 6 (control), 11 (1%
betaine) and 7 (5% betaine) in females. No treatment-related changes in animal performance were
identified. Body weights of rats administered 5% betaine in the diet were statistically significantly
lower compared with the control group in males at weeks 2–5 and in females at weeks 2 and 3. At
later time points, male rats of the low- and high-dose group showed significantly higher body weights
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(at weeks 21, 25, 29, 33, 37 and 41, and at weeks 21, 25, 33, 37, 49 and 97, respectively). Final body
weights did not differ significantly from those of the control group. Feed intake in both test groups
was significantly different compared with the control group during numerous time periods in males and
females. Feed intake did not show a consistent correlation with dose and body weight.
Haematology analysis at the end of the treatment period showed significantly lower MCV and MCH
in females of the high-dose group compared with the control group. Females of the low-dose group
showed a significantly higher MCH. Platelet counts were significantly higher in low- and high-dose
males (dose-related) and high-dose females. Organ weight determinations at necropsy showed a
significantly increased kidney weight in low-dose males (absolute weight), high-dose males (absolute
and relative weight) and high-dose females (absolute weight). Liver weight was significantly increased
in low-dose males (absolute weight), low-dose females (relative weight) and high-dose females
(absolute and relative weight). Males of the low-dose group showed a higher absolute heart weight
and females of the high-dose group a lower relative heart weight. Females of the high-dose group also
had a higher absolute lung weight.
Macroscopic examinations revealed a higher number of females in the low- and high-dose group
(dose-related) showing pale spots in the liver; there was also a slight increase in high-dose males.
Microscopic examinations of tissues showed that the overall tumour incidence (number of cases and
percentage) of males as well as females was comparable in the test groups and the control group
(males: 49 (98%) in all three groups; females: control 43 (86%), 1% betaine 43 (87.8%) and 5%
betaine 40 (80%)). No statistically significant increase in the incidence of any tumour type was
observed in both male and female animals of the high-dose group when compared with the control
group. Nevertheless, regarding the liver, three low-dose males and four high-dose males as well as one
high-dose female showed liver tumours (hepatocellular adenomas plus carcinomas). In this study, no
tumours were identified in the control group; however, historical control data show that hepatocellular
adenomas and carcinomas occur spontaneously in this strain of rats (Haseman et al., 1998; Ando
et al., 2008). Regarding the kidneys, one male of the high-dose group showed a renal cell adenoma,
and one female of the mid-dose group, which died during the treatment period, showed a
nephroblastoma. The only significant differences identified (thyroid C-cell adenoma, adrenal gland
pheochromocytoma, testis interstitial cell tumour, pituitary gland adenocarcinoma and uterus
endometrial stromal polyp) related to decreases in tumour incidences and/or only occurred in the low-
dose group. Other histopathological changes in these and other tissues occurred with similar incidence
and severity in all treatment groups. The Panel considers that the tumours observed are not related to
treatment with betaine and do not raise concern with regard to carcinogenicity of the NF.
The Panel notes that several of the changes in haematology and clinical chemistry parameters as
well as in organ weights in the chronic part of the study had also been observed in the subchronic
toxicity study by TNO BIBRA (Unpublished study report, 2001a,b), previously evaluated by EFSA
(2005). Some of these changes were also seen in the carcinogenicity part after 104 weeks. Since an
increase in platelet counts occurred in male rats already at the lowest dose level, the Panel considers
that it is not possible to derive a NOAEL from this combined chronic toxicity/carcinogenicity study.
The Panel considered the dose-related increase in platelet counts in male rats as the critical effect
and subjected the data from the 52-week chronic oral toxicity study to a benchmark dose (BMD)
modelling, using the EFSA web-tool for BMD analysis,4 which is based on PROAST software. As
indicated in the EFSA Guidance on the BMD approach (EFSA Scientific Committee, 2017), the
benchmark response (BMR) default value of 5% has been used to calculate the BMD05. Confidence
intervals (90%) were estimated around the BMDs and the corresponding values for the upper and
lower confidence limits (BMDUs and BMDLs, respectively) were calculated (BMD report available in
Annex A).
The lowest BMDL05 of 131 mg/kg bw is considered by the Panel as the reference point (RP) for the
risk characterisation.
3.8.5. Reproduction and developmental toxicity studies
No reproduction or developmental toxicity studies on the NF conducted according to OECD
guidelines were identified in the scientific literature.
The applicant has referred to a study, in which the betaine concentration in tissues of developing
rats was examined (Clow et al., 2008). Betaine was administered to pregnant Sprague–Dawley rats
4 https://efsa.openanalytics.eu/
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(5/group) via the diet at a level of 0% (control diet) or 0.3% from gestation day 5 to postnatal day
50. After weaning, pups were fed either the same diet as their mother or the alternative diet. While
the betaine content of plasma, liver and kidneys increased in pups fed the betaine diet following
weaning, the presence of betaine in the maternal diet had no effect on pup betaine content or on two
enzymes of betaine metabolism. No significant difference in pup growth was observed between
groups. No further safety-related endpoints were evaluated.
3.8.6. Effects on glutathione homoeostasis
A concern about potential effects of betaine on glutathione homoeostasis was addressed by the
Panel in 2005 (EFSA, 2005). It had been suggested that an acute dose of betaine enhances metabolic
reactions in the methionine cycle, but inhibits cystathionine and cysteine synthesis, leading to a
decrease in supply of cysteine for glutathione synthesis in mice and rats (Kim et al., 2003).
The applicant has provided new data related to this issue.
Administration of betaine (1%) in drinking water for up to 3 weeks to male ICR mice did not affect
cysteine or glutathione levels in plasma, kidneys and liver (Kim and Kim, 2005).
After administration of betaine (1.5%) in drinking water for 4 weeks, no changes in hepatic
glutathione levels were observed in male Wistar rats (Balkan et al., 2005).
In a study with male Fischer 344 rats, betaine was administered in the diet at levels of 1% or 2%
for 2 weeks. A statistically significant dose-related increase in hepatic glutathione levels compared with
the control group was observed, while serum concentrations were significantly higher in the 1%
betaine group and significantly lower in the 2% betaine group (Okada et al., 2011).
The Panel notes that these studies do not show a negative impact of betaine on glutathione levels.
3.8.7. Human studies
The applicant provided a number of human studies on betaine. Several studies in healthy subjects
investigated the effect of betaine on plasma homocysteine concentrations (Brouwer et al., 2000; Olthof
et al., 2003) or on physical exercise (Armstrong et al., 2008; Hoffman et al., 2009; Lee et al., 2010a;
Trepanowski et al., 2011; del Favero et al., 2012; Pryor et al., 2012) at a single dose of 5 g/day
(Armstrong et al., 2008), doses up to 2.5 g/day for periods up to 15 days (Hoffman et al., 2009; Lee
et al., 2010a; Trepanowski et al., 2011; del Favero et al., 2012; Pryor et al., 2012) or at 6 g/day for
6 weeks (Brouwer et al., 2000; Olthof et al., 2003). These studies did not investigate safety-related
endpoints, although one short-period study, in which 13 men received 2.5 g of betaine for 14 days,
reported that no adverse effects were noted with either betaine or placebo supplementation and that
treatment with betaine was well tolerated (Trepanowski et al., 2011).
The randomised, cross-over study by Atkinson et al. (2009) investigated blood lipids parameters in
eight healthy males who consumed either a betaine-rich diet or a betaine supplement for 14 days. The
Panel considers that no conclusion can be drawn from this uncontrolled study on the effect of betaine
on blood lipids.
In a randomised, double-blind, placebo-controlled, cross-over study by Olthof et al. (2006) on the
effect of supplementation with 6 g/day of betaine over a period of 6 weeks on flow-mediated dilatation
in 39 healthy men and women, aged 50–70 years, adverse events were reported. A total of 112 non-
serious adverse events (mainly headache and common cold/influenza), were noted in 31 participants.
However, no details were provided on the number of the adverse events in the betaine or placebo
group. The Panel considers that no conclusion can be drawn from this study on the safety of betaine.
The randomised, placebo-controlled, double-blind parallel study by Schwab et al. (2002) investigated
effects of supplementation with 6 g/day of betaine over 12 weeks in 42 obese, but otherwise healthy
white subjects (14 men, 25–60 years old, body mass index (BMI) 33.5  3.1 kg/m2) treated with a low-
energy diet. No power calculation was reported. Body weight, resting energy expenditure, fat mass,
diastolic blood pressure, fasting serum asparagine aminotransferase, alanine aminotransferase and
c-glutamyltransferase concentrations decreased in both groups without a significant difference between
the groups. The fasting serum alkaline phosphatase concentration showed a tendency to increase in the
control group but not in the betaine group. Plasma homocysteine concentrations decreased in the
betaine group. There were no statistically significant differences between groups with regard to fasting
plasma glucose, serum thyroid-stimulating hormone (TSH) or creatinine concentrations. No significant
changes in serum total or lipoprotein lipid concentrations were found in either of the groups, but at the
end of the intervention, serum total (5.5  1.1 vs 4.9  0.6 mmol/L) and low-density lipoprotein
(LDL)-cholesterol (3.7  1.0 vs 3.0  0.5 mmol/L) concentrations were higher in the betaine group
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than in the control group (p < 0.05). The adverse side effects monitored, through a self-reporting form
included gastrointestinal illnesses, thirst, dry mouth, increased urination, and preference for salt or salty
food. No adverse effects were systematically reported by the subjects in either of the groups.
Olthof et al. (2005) reported data on blood lipids that were combined post hoc from three
individual (two parallel and one cross-over) placebo-controlled, randomised intervention studies in 151
healthy subjects (81 men, 30–70 years old) (Steenge et al., 2003; Olthof et al., 2003, 2006; see also
Section 3.6). The primary outcome of the intervention studies was the effect of betaine
supplementation of 6 g/day for 6 weeks on plasma homocysteine concentrations of healthy subjects
selected for highest total plasma homocysteine concentrations. In two of the three studies, the
increase in total- and LDL-cholesterol concentrations was significant. By combining the data from all
three studies, the increase relative to placebo was 0.36 mmol/L (95% CI 0.25–0.46) for LDL-
cholesterol and 0.14 mmol/L (95% CI 0.04–0.23) for triacylglycerol concentrations (p < 0.05). The
ratio of total to high-density lipoprotein (HDL)-cholesterol increased by 0.23 (95% CI 0.14–0.32)
(p < 0.05) relative to placebo. Concentrations of HDL-cholesterol were not affected. Doses of betaine
lower than 6 g/day (1.5 or 3 g/day) also raised LDL-cholesterol, but these changes were not
statistically significant. The adverse events reported in the intervention studies were not serious and
apparently related to methionine loading.
Another randomised, placebo-controlled, double-blind intervention study (Schwab et al., 2011;
unpublished study report of the study, undated) investigated the effects of a 6-month intervention with
4 g/day of betaine (BetaPower
TM
) on serum lipid profile among haematology and blood chemistry
parameters in 63 healthy volunteers (13 men; 27  8 years old; BMI 22.6  2.4 kg/m2). No power
calculation was reported. There were no statistically significant differences within or between groups
with regard to body weight, BMI, systolic and diastolic blood pressure over the 24-week period. No
statistically significant difference (within or between groups) was reported for platelet counts (9109/L)
(284  68 at week 0 and 272  65 at week 24 in the betaine group; 278  56 at week 0 and
262  52 at week 24 in the control group). Plasma plasminogen activator inhibitor 1 (PAI-1)
concentration increased in the betaine group (from 7.19  2.91 at week 0 to 8.85  3.78 AU/mL at
week 24; p = 0.028) and decreased in the control group, resulting in a statistically significantly higher
concentration in the betaine group than in the control group at the end of the study (8.85  3.78 vs
6.25  2.38 AU/mL, p = 0.006). Although increased PAI-1 concentration may slow down the fibrinolytic
process, the levels of PAI-1 were within the normal range throughout the study. There were no
statistically significant differences between and within groups in serum total cholesterol (4.4  0.8 at
week 0 and 4.6  0.8 at week 24 in the betaine group; 4.7  0.8 at week 0 and 4.6  0.9 at week 24
in the control group) and LDL-cholesterol (2.64  0.70 at week 0 and 2.74  0.65 at week 24 in the
betaine group; 2.63  0.72 at week 0 and 2.61  0.74 at week 24 in the control group) concentrations
(mmol/L). There were no statistically significant differences between groups in the other parameters
investigated which included haemostatic factors, other blood lipids parameters (e.g. HDL-cholesterol,
triglycerides, oxidised LDL-cholesterol), plasma high-sensitivity C-reactive protein, blood haemoglobin,
haematocrit and leucocytes; homocysteine, serum creatinine, c-glutamyltransferase and alanine
aminotransferase concentrations.
Another randomised, placebo-controlled, double-blind intervention study investigated the effects of
a 3-month intervention with 4 g/day of betaine (BetaPowerTM) on serum lipid profile among
haematology and blood chemistry parameters in 32 individuals (18 men; mean age: 54–55 years;
mean BMI: 29 kg/m2) with metabolic syndrome according to the WHO criteria (unpublished study
report of the study, undated). No power calculation was reported. No statistically significant differences
(within or between groups) were reported in the parameters investigated except for serum total and LDL
cholesterol, serum apolipoprotein B concentrations which increased in the betaine group (total cholesterol:
from 5.7  0.8 to 6.2  0.91 mmol/L; LDL-cholesterol: from 3.74  0.71 to 4.06  0.77 mmol/L; serum
apolipoprotein B: from 1.19  0.20 to 1.30  0.25 g/L); plasma homocysteine concentration which
decreased in the betaine group. No statistically significant difference (within or between groups) was
reported in platelet counts (9109/L) (295  81 at week 0 and 287  80 at week 12 in the betaine group;
273  43 at week 0 and 256  45 at week 12 in the placebo group).
Upon an EFSA request for additional information, the applicant provided an ad hoc Expert report on
platelet counts from a recently completed double-blind intervention study (unpublished study report,
2017). In this study, 75 male adults (mean age: 55–58 years; mean BMI: 32.5–35.3 kg/m2) with
metabolic syndrome according to the International Diabetes Federation were randomised to receive
either supplementation of betaine (BetaPowerTM) (0.5 or 2.5 g/day) or placebo (maltodextrin) (n = 25
per group) for 6 months. Sample size was calculated based on the primary end-point of the study (i.e.
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change in body fat). There was no statistically significant difference over time (between or within
groups) in platelet counts (9109/L) (in the high-betaine group: 244.2  55.0 at week 0 and
251.6  63.8 at week 24; in the low-betaine group: 236.9  51.5 at week 0 and 228.1  50.5 at
week 24; in the placebo group: 217.2  67.7 at week 0 and 219.0  68.8 at week 24).
Upon an EFSA request for additional information, the applicant provided the publication of a
double-blind intervention study in which 20 Japanese males (mean age: 43–46 years; mean BMI:
24–25 kg/m2) with mild fatty liver (not requiring medication) were randomised to receive either
supplementation of betaine 3 g/day (Betafin BF®) or placebo (maltodextrin) (n = 10 per group) for
12 weeks (Tiihonen et al., 2016). No power calculation was reported. Several parameters (e.g. liver fat
content, liver enzyme activities and other markers of liver and kidney function, visceral and
subcutaneous fat area, blood parameters) were investigated and adverse events were recorded
throughout the study. Except for HDL-cholesterol concentration (which increased significantly in the
betaine group but not in the placebo group) the authors did not report any statistically significant
differences between groups in the parameters investigated including platelet counts (9109/L) (in the
betaine group: 237.4  40.5 at day 0 and 243.0  35.4 at week 12; in the placebo group:
235.5  38.1 at day 0 and 239.7  36.3 at week 12), total cholesterol (in the betaine group:
5.76  0.97 at day 0 and 6.32  0.8 at week 12; in the placebo group: 5.79  0.81 at day 0 and
5.93  0.69 at week-12) and LDL-cholesterol (in the betaine group: 3.57  0.94 at day 0 and
3.98  0.79 at week 12; in the placebo group: 3.86  0.73 at day 0 and 3.93  0.71 at week 12)
concentrations (mmol/L). No differences between groups in the frequency of adverse events were
reported: five non-serious adverse events occurred in the betaine group and 12 non-serious adverse
events occurred in the placebo group. The authors indicated that all events were mild and symptoms
resolved without interruption of the intervention with the exception of one adverse event (loose stool)
in the betaine group which could be related to the intervention.
The Panel notes that doses of 6 g/day of betaine for 12 weeks were reported to increase LDL- and
total cholesterol concentrations in healthy obese subjects on a low-energy diet (Schwab et al., 2002)
as well as in two of three studies providing 6 g/day of betaine for 6 weeks in healthy subjects selected
for high plasma homocysteine concentrations (Olthof et al., 2005). A significant increase in total and
LDL-cholesterol concentrations (0.5 and 0.32 mmol/L, respectively) was also seen in a study providing
4 g/day of betaine for 3 months in overweight subjects with metabolic syndrome (unpublished study
report of the study, undated), but not in normal weight subjects receiving 4 g/day of betaine for
6 months (Schwab et al., 2011) or 3 g/day of betaine for 12 weeks (Tiihonen et al., 2016). The
Panel considers that the results indicate that 4 g/day betaine and above may increase total and
LDL-cholesterol concentrations (Schwab et al., 2002; Olthof et al., 2005; EFSA NDA Panel, 2011;
unpublished study report of the study, undated).
The Panel notes that platelet counts were not statistically significantly different in subjects
provided with 2.5, 3 or 4 g of betaine per day for 12 weeks up to 6 months from respective control
groups (Schwab et al., 2011; unpublished study report, undated; Unpublished study report, 2017;
Tiihonen et al., 2016) and that platelet counts over time in these studies were within normal ranges
(150–450 9109/L).
Methyl donors such as betaine may promote methylation of DNA; whether an excess intake of
methyl donors may be associated with altered DNA methylation and diseases is under discussion
(Shorter et al., 2015). Changes in DNA methylation status are hypothesised to be involved in different
stages of colorectal cancer (Ashktorab and Brim, 2014). No associations between dietary choline and
betaine intake and risk of colorectal cancer were found in 47,302 men in the Health Professionals
Follow-up Study from 1986 to 2004; however, absolute values of choline and betaine intakes were not
provided (Lee et al., 2010b).
Betaine is a precursor of trimethylamine (TMA) formed by gut microbiota. TMA can either be
oxidised to trimethylamine oxide (TMAO) by the gut microbiota or by human hepatic flavin
monooxygenase 3. Increased TMAO levels have been associated with higher risk for adverse cardiac
events and mortality in patients with chronic heart failure and in patients with type 2 diabetes mellitus
(Trøseid et al., 2015; Tang et al., 2017).
The relationship between serum concentrations of TMAO and its precursors (choline, carnitine and
betaine) and incident colorectal cancer risk was also investigated in a nested case–control study of
male smokers in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study (Guertin et al.,
2017). Men with higher serum choline at baseline had approximately threefold greater risk of
developing colorectal cancer over the ensuing 14  10 years while the association between serum
TMAO, carnitine or betaine and colorectal cancer risk was not statistically significant.
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The Panel considers that it is currently not possible to draw conclusions on potentially adverse
consequences of the contribution of betaine to methylation-related processes and TMA-related
processes.
3.9. Allergenicity
The NF is produced from sugar beet which is recognised not to be allergenic.
The production process may also include a fermentation step using the yeast S. cerevisiae, which is
known to have allergenicity properties. In the specifications of the NF, the applicant has proposed a
residual protein content of up to 1 mg/g for the NF.
The Panel notes that the risk of allergenicity for people who are allergic to yeast cannot be
excluded.
4. Discussion
The NF which is the subject of the application is betaine, in anhydrous and monohydrate form,
which is obtained from processing of sugar beets (i.e. molasses, vinasses or betaine glycerol). The
information provided on the composition, the specifications, the batch-to-batch variability, stability
and production process of the NF is sufficient and does not raise concerns about the safety of the
NF.
The NF is proposed to be used in foods intended to meet additional requirements for intense
muscular effort (i.e. carbohydrate-rich energy food products, carbohydrate-electrolyte solutions, and
protein/protein components) with a proposed intake of 2.5 g betaine per day. The target population
proposed by the applicant is sports people above 10 years of age (adolescents and adults).
Based on the proposed uses and maximum use levels and the food consumption data from the UK
NDNS Rolling Survey Programme (2008–2011), the 95th percentile anticipated intake of the NF was
calculated: 1.30 g/day (26.4 mg/kg bw per day) for adolescents and 2.93 g/day (35.7 mg/kg bw per
day) for adults.
Betaine is naturally present in foods, such as beets, spinach and wheat flour. However, betaine
exposure from the diet does not only derive from the consumption of betaine-containing foods but
also from choline-containing foods as most choline is irreversibly oxidised to betaine in the body. The
total exposure to betaine resulting from dietary intake calculated from the sum of highest reported
mean intakes across studies can be estimated to be about 830 mg/day.
The Panel considers that consumption of the NF is not nutritionally disadvantageous.
The Panel considers that the microbiological information provided does not raise safety concerns.
The Panel notes that the risk of allergenicity for people who are allergic to yeast, which can be
used in the production process, cannot be excluded.
The available data indicate that, following oral ingestion, betaine is rapidly absorbed, released to
the portal circulation and transported to the liver where significant presystemic metabolism occurs.
Only a small amount of betaine and its metabolite DMG are excreted in the urine.
The Panel considers that there is no concern with respect to genotoxicity of the NF.
Several repeated-dose oral toxicity studies with the NF in rodents and piglets have been
provided by the applicant, some of which were assessed by the NDA Panel in 2005. At that time,
the Panel could not derive a NOAEL for the NF from the 28-day and 90-day oral toxicity studies.
The applicant has now provided a chronic oral toxicity and carcinogenicity study with the NF.
The Panel notes that several of the changes in haematology and clinical chemistry parameters as
well as organ weight changes observed in this study were also seen in the 90-day toxicity study
previously evaluated in 2005. Since an increase in platelet counts in male rats was observed, which
is regarded as a critical effect, already occurred at the lowest dose level, the Panel considers that
it is not possible to derive a NOAEL for this combined chronic toxicity/carcinogenicity study.
Therefore, in order to derive an adequate RP, the Panel subjected the data on platelet counts in
male rats from the chronic oral toxicity study to BMD modelling. The lowest BMDL05 of 131 mg/kg
bw was considered by the Panel as the RP for the risk characterisation. The ratio between this RP
and the anticipated daily intake of the NF in adults and adolescents results in Margins of Exposure
of 3.6 and 5, which are generally regarded as not sufficient.
However, the Panel notes that the total exposure to betaine resulting from dietary intake calculated
from the sum of highest reported mean intakes across studies (about 830 mg/day, i.e. 12 mg/kg bw5
5 By using mean bw of 70 kg for adults (EFSA Scientific Committee, 2012).
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per day for adults; 19 mg/kg bw6 per day for adolescents aged 10–14 years and 13 mg/kg bw7 per
day for adolescents aged 14–18 years) is not known to be associated with adverse effects.
Moreover, the Panel notes that four human intervention studies are available with exposure levels
of 4 g/day of betaine supplementation (which corresponds to 57 mg/kg bw5 per day for adults) for up
to 6 months. In these studies, no adverse effects on platelet counts were noted. The Panel also notes
that a significant increase in total and LDL-cholesterol concentrations have been reported at intakes of
4 g/day of betaine in overweight subjects with metabolic syndrome but not in healthy subjects, nor at
intakes of 3 g/day. In this context, the Panel considers that 4 g/day of betaine can be taken as a RP
and that an uncertainty factor of 10 is sufficient to account for inter-individual variability (EFSA
Scientific Committee, 2012). Therefore, an amount of 400 mg/day of betaine (i.e. 6 mg/kg bw5 per
day for adults) in addition to the background exposure is considered as safe.
5. Conclusions
The Panel concludes that the safety of the NF, betaine, at the intended uses and use levels as
proposed by the applicant (2.5 g/day) has not been established.
The Panel considers that the NF is safe to be used at maximum intake of 6 mg/kg bw per day in
the target population (sports people above 10 years of age) in addition to the background exposure.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientific opinion on the safety of betaine. Letter SANTE/E2/SS/ks D(2016)
1592858 - Ref. Ares(2016)1594324, dated 4 April 2016.
2) On 14 April 2016 EFSA received the following documentation: technical dossier ‘request for
authorisation of betaine’, which was submitted by DuPont Nutritional Biosciences ApS; initial
assessment report carried out by the Food Safety Authority of Finland: ‘application
concerning betaine as a novel food ingredient’; Member States’ comments and objections;
response by the applicant to the initial assessment report.
3) Upon a request by EFSA for missing information, on 7 June 2016, EFSA received the missing
information as submitted by the applicant.
4) Additional data were provided by the applicant on 17/2/2017 and on 20/9/2017.
5) During its meeting on 25 October 2017, the NDA Panel, having evaluated the data, adopted
a scientific opinion on the safety of betaine as a novel food pursuant to Regulation (EC)
No 258/97.
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Annex A – Benchmark Dose Modelling Report
Data description
The endpoint to be analysed is: platelet counts in male F344/DuCrj rats from the 52-week chronic
oral toxicity study (platelet_mean, SD = standard deviation, n = number of animals per group;
Unpublished study report, 2002).
Data used for analysis:
Dose platelet_mean SD n
0 62.3 4.6 10
426 68.9 6.2 10
975 77.3 1.3 10
2,104 78.8 3.2 10
Selection of the BMR
The benchmark dose (BMD) is defined as the dose that corresponds with a 5% estimated change
in response compared with the background response. The benchmark response (BMR) is the estimated
response corresponding with the BMD of interest.
A 90% confidence interval around the BMD will be estimated, the lower bound is reported by BMDL
and the upper bound by BMDU.
Software used
Results are obtained using the EFSA web-tool for BMD analysis. Fitting benchmark dose models is
based on the R-package PROAST, version 64.9.
Results
Response variable: mean platelets counts.
Fitted models
Model Converged loglik npar AIC
Full Yes 56.50 5 103.00
m1- Yes 30.63 2 57.26
Expon. m3- Yes 53.36 4 98.72
Expon. m5- Yes 56.50 5 103.00
Hill m3- Yes 53.27 4 98.54
Hill m5- Yes 56.50 5 103.00
Estimated model parameters
EXP
estimate for var- : 0.003472
estimate for a- : 62.13
estimate for CED- : 270.7
estimate for c- : 1.267
estimate for d- : 1.925
HILL
estimate for var- : 0.003472
estimate for a- : 62.13
estimate for CED- : 311.9
estimate for c- : 1.269
estimate for d- : 3.278
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Final BMD values
Model BMDL BMDU BMD
Expon. m5- 131 403 270
Hill m5- 158 409 310
Lowest BMDL and highest BMDU values
Subgroup bmdl.lowest bmdu.highest
All 131 409
Visualisation
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